Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Safusidenib (AB-218, DS-1001)

G307

Nuvation Bio · Phase 3 · Not yet recruiting · Enrollment 140

NCT07712757

Catalyst Primary completion. 05.2029. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy

No efficacy figure is in this file for this study.